États-Unis · Agences & temps réel · PR Newswire

HanchorBio and Aston Sci Join Forces to Unlock the Potential of Next-Generation Immunotherapy Through Cancer Vaccine Combinations

Publié par PR Newswire · États-Unis il y a 3 h

Strategic collaboration pairs HCB101 (macrophage CD47-SIRPα blockade) with Aston Sci's Phase 2 HER2-directed DNA vaccine (AST-301) to drive durable, dual innate/adaptive antitumor…

Lire l'article complet sur PR Newswire Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.prnewswire.com)

HanchorBio and Aston Sci Join Forces to Unlock the Potential of Next-Generation Immunotherapy Through Cancer Vaccine Combinations

À lire aussi

Spotify Technology S.A. Releases Results for Third Quarter 2026

Coastal construction projects threaten the mangrove forest that protects Vietnam’s biggest city

Episode 49: Trump’s Tariffs Give Forced-Labor Activists an Opening

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows

HanchorBio and Aston Sci Join Forces to Unlock the Potential of Next-Generation Immunotherapy Through Cancer Vaccine Combinations

Partager

À lire aussi

Spotify Technology S.A. Releases Results for Third Quarter 2026

Coastal construction projects threaten the mangrove forest that protects Vietnam’s biggest city

Episode 49: Trump’s Tariffs Give Forced-Labor Activists an Opening

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows